Market closedNon-fractional

Black Diamond Therapeutics/BDTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Black Diamond Therapeutics

Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Ticker

BDTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

54

BDTX Metrics

BasicAdvanced
$323M
Market cap
-
P/E ratio
-$1.67
EPS
2.51
Beta
-
Dividend rate
$323M
2.51
7.049
6.835
20.479
23.532
-38.27%
-78.81%
2.91
2.91
-4.046
-29.81%
-11.11%

What the Analysts think about BDTX

Analyst Ratings

Majority rating from 6 analysts.
Buy

BDTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$18M
-6.19%
Profit margin
0.00%
NaN%

BDTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 19.54%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.52
-$0.45
-$0.34
-$0.35
-
Expected
-$0.54
-$0.49
-$0.47
-$0.44
-$0.39
Surprise
-2.95%
-7.50%
-27.04%
-19.54%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Black Diamond Therapeutics stock?

Black Diamond Therapeutics (BDTX) has a market cap of $323M as of July 23, 2024.

What is the P/E ratio for Black Diamond Therapeutics stock?

The price to earnings (P/E) ratio for Black Diamond Therapeutics (BDTX) stock is 0 as of July 23, 2024.

Does Black Diamond Therapeutics stock pay dividends?

No, Black Diamond Therapeutics (BDTX) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Black Diamond Therapeutics dividend payment date?

Black Diamond Therapeutics (BDTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Black Diamond Therapeutics?

Black Diamond Therapeutics (BDTX) has a beta rating of 2.51. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Black Diamond Therapeutics stock

Buy or sell Black Diamond Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing